Division of Genomic Medicine, Department of Medicine, The George Washington University School of Medicine and Health Sciences, Washington, District of Colombia, United States of America.
PLoS One. 2013;8(1):e54213. doi: 10.1371/journal.pone.0054213. Epub 2013 Jan 23.
MicroRNAs (miRNAs) contribute to cancer initiation and progression by silencing the expression of their target genes, causing either mRNA molecule degradation or translational inhibition. Intraductal epithelial proliferations of the breast are histologically and clinically classified into normal, atypical ductal hyperplasia (ADH), ductal carcinoma in situ (DCIS) and invasive ductal carcinoma (IDC). To better understand the progression of ductal breast cancer development, we attempt to identify deregulated miRNAs in this process using Formalin-Fixed, Paraffin-Embedded (FFPE) tissues from breast cancer patients. Following tissue microdissection, we obtained 8 normal, 4 ADH, 6 DCIS and 7 IDC samples, which were subject to RNA isolation and miRNA expression profiling analysis. We found that miR-21, miR-200b/c, miR-141, and miR-183 were consistently up-regulated in ADH, DCIS and IDC compared to normal, while miR-557 was uniquely down-regulated in DCIS. Interestingly, the most significant miRNA deregulations occurred during the transition from normal to ADH. However, the data did not reveal a step-wise miRNA alteration among discrete steps along tumor progression, which is in accordance with previous reports of mRNA profiling of different stages of breast cancer. Furthermore, the expression of MSH2 and SMAD7, two important molecules involving TGF-β pathway, was restored following miR-21 knockdown in both MCF-7 and Hs578T breast cancer cells. In this study, we have not only identified a number of potential candidate miRNAs for breast cancer, but also found that deregulation of miRNA expression during breast tumorigenesis might be an early event since it occurred significantly during normal to ADH transition. Consequently, we have demonstrated the feasibility of miRNA expression profiling analysis using archived FFPE tissues, typically with rich clinical information, as a means of miRNA biomarker discovery.
微小 RNA(miRNAs)通过沉默靶基因的表达来促进癌症的发生和发展,导致 mRNA 分子降解或翻译抑制。乳腺导管上皮增生在组织学和临床上分为正常、非典型导管增生(ADH)、导管原位癌(DCIS)和浸润性导管癌(IDC)。为了更好地理解乳腺导管癌发展的进程,我们试图使用来自乳腺癌患者的福尔马林固定、石蜡包埋(FFPE)组织来鉴定此过程中失调的 miRNAs。在组织微切割后,我们获得了 8 个正常、4 个 ADH、6 个 DCIS 和 7 个 IDC 样本,这些样本经过 RNA 分离和 miRNA 表达谱分析。我们发现,miR-21、miR-200b/c、miR-141 和 miR-183 在 ADH、DCIS 和 IDC 中与正常相比均持续上调,而 miR-557 在 DCIS 中则唯一下调。有趣的是,最显著的 miRNA 失调发生在正常向 ADH 过渡期间。然而,该数据并未揭示离散肿瘤进展阶段之间 miRNA 逐步改变,这与先前关于不同阶段乳腺癌 mRNA 谱分析的报道一致。此外,在 MCF-7 和 Hs578T 乳腺癌细胞中,miR-21 下调后,两个重要的 TGF-β 通路分子 MSH2 和 SMAD7 的表达得到恢复。在本研究中,我们不仅鉴定了一些潜在的候选 miRNA 用于乳腺癌,而且还发现 miRNA 表达失调在乳腺肿瘤发生过程中可能是一个早期事件,因为它在正常向 ADH 过渡时就显著发生。因此,我们已经证明了使用存档的 FFPE 组织进行 miRNA 表达谱分析的可行性,通常这些组织具有丰富的临床信息,是 miRNA 生物标志物发现的一种手段。